Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

ClinicalTrials.gov ID: NCT06264310

Public ClinicalTrials.gov record NCT06264310. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 3:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Double-Blind, Placebo-Controlled, Dose Range Finding Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Combined With Standard of Care Versus Standard of Care Alone in Outpatients With Worsening Heart Failure (WHF)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Study Aims to Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

Study identification

NCT ID
NCT06264310
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
River 2 Renal Corp.
Industry
Enrollment
33 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 1, 2024 (Actual)
Primary completion
Nov 4, 2024 (Actual)
Completion
Nov 25, 2024 (Actual)
Last update posted
Jun 22, 2026

2024

United States locations

U.S. sites
8
U.S. states
4
U.S. cities
8
Facility City State ZIP Site status
Thomas Hospital Fairhope Alabama 36532 —
C&R Research Fort Meyers Florida 33919 —
C&R Research Hialeah Florida 33013 —
Encore Clinical Research Inverness Florida 34452 —
Encore Clinical Research Jacksonville Florida 32216 —
Amavita Clinical Research Miami Florida 33137 —
Lake Country Eatonton Georgia 31024 —
J&S Studies College Station Texas 77845 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06264310, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 22, 2026 · Synced Oct 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06264310 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →